Vanda Pharmaceuticals’ tasimelteon has shown the ability to reset the body clock and to align it to a constant 24-hour day in patients suffering from Non-24-Hour Sleep-Wake Disorder (Non-24-Hour Disorder).
Tasimelteon is a circadian regulator in development for the treatment of Non-24-Hour Disorder in totally blind individuals with no light perception.
This observation was made in four patients during the initial run-in segment of the RESET study. RESET is a Phase III study of the maintenance effect of tasimelteon in the treatment of Non-24-Hour Disorder.
The company is currently investigating the efficacy of tasimelteon in Non-24-Hour Disorder in two Phase III studies, SET and RESET, which are ongoing and expected to be completed by the end of 2012. Vanda Pharmaceuticals CEO and president Mihael H Polymeropoulos said the finding provides the evidence that tasimelteon is able to reset the body clock in patients with Non-24-Hour Disorder.